TY - JOUR
T1 - Advanced Pulmonary and Cardiac Support of COVID-19 Patients
T2 - Emerging Recommendations from ASAIO - A Living Working Document
AU - Rajagopal, Keshava
AU - Keller, Steven P.
AU - Akkanti, Bindu
AU - Bime, Christian
AU - Loyalka, Pranav
AU - Cheema, Faisal H.
AU - Zwischenberger, Joseph B.
AU - El Banayosy, Aly
AU - Pappalardo, Federico
AU - Slaughter, Mark S.
AU - Slepian, Marvin J.
N1 - Publisher Copyright:
© 2020 Lippincott Williams and Wilkins. All rights reserved.
PY - 2020/5/1
Y1 - 2020/5/1
N2 - The severe acute respiratory syndrome-CoV-2 is an emerging viral pathogen responsible for the global coronavirus disease 2019 pandemic resulting in significant human morbidity and mortality. Based on preliminary clinical reports, hypoxic respiratory failure complicated by acute respiratory distress syndrome is the leading cause of death. Further, septic shock, late-onset cardiac dysfunction, and multiorgan system failure are also described as contributors to overall mortality. Although extracorporeal membrane oxygenation and other modalities of mechanical cardiopulmonary support are increasingly being utilized in the treatment of respiratory and circulatory failure refractory to conventional management, their role and efficacy as support modalities in the present pandemic are unclear. We review the rapidly changing epidemiology, pathophysiology, emerging therapy, and clinical outcomes of coronavirus disease 2019; and based on these data and previous experience with artificial cardiopulmonary support strategies, particularly in the setting of infectious diseases, provide consensus recommendations from American Society for Artificial Internal Organs. Of note, this is a living document, which will be updated periodically, as additional information and understanding emerges.
AB - The severe acute respiratory syndrome-CoV-2 is an emerging viral pathogen responsible for the global coronavirus disease 2019 pandemic resulting in significant human morbidity and mortality. Based on preliminary clinical reports, hypoxic respiratory failure complicated by acute respiratory distress syndrome is the leading cause of death. Further, septic shock, late-onset cardiac dysfunction, and multiorgan system failure are also described as contributors to overall mortality. Although extracorporeal membrane oxygenation and other modalities of mechanical cardiopulmonary support are increasingly being utilized in the treatment of respiratory and circulatory failure refractory to conventional management, their role and efficacy as support modalities in the present pandemic are unclear. We review the rapidly changing epidemiology, pathophysiology, emerging therapy, and clinical outcomes of coronavirus disease 2019; and based on these data and previous experience with artificial cardiopulmonary support strategies, particularly in the setting of infectious diseases, provide consensus recommendations from American Society for Artificial Internal Organs. Of note, this is a living document, which will be updated periodically, as additional information and understanding emerges.
KW - ARDS
KW - coronavirus
KW - extracorporeal membrane oxygenation
KW - mechanical circulatory support
KW - pandemic
KW - shock
UR - http://www.scopus.com/inward/record.url?scp=85084273013&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85084273013&partnerID=8YFLogxK
U2 - 10.1161/CIRCHEARTFAILURE.120.007175
DO - 10.1161/CIRCHEARTFAILURE.120.007175
M3 - Article
C2 - 32357074
AN - SCOPUS:85084273013
SN - 1941-3289
VL - 13
SP - E007175
JO - Circulation: Heart Failure
JF - Circulation: Heart Failure
IS - 5
ER -